文献速递心律失常

心房颤动高合并症负担患者的早期节律控制

Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden.
PubMed 文献 · Circulation · 2022-08-15

该研究为EAST-AFNET4的预设亚组分析,比较早期节律控制与常规治疗在不同合并症负担房颤患者中的有效性与安全性。结果显示CHA2DS2-VASc≥4患者接受早期节律控制可减少心血管死亡、卒中或心衰/ACS住院复合终点,而评分<4者未见获益且主要安全终点事件增加。

要点

  • CHA2DS2-VASc≥4的近期诊断房颤患者可考虑早期节律控制以降低心血管复合终点。
  • CHA2DS2-VASc<4患者早期节律控制未减少主要疗效终点,且主要安全终点事件增加。
  • 疗效终点交互作用P=0.037,安全性终点交互作用P=0.008。

核心结论

  • 近期诊断房颤且CHA2DS2-VASc评分≥4的患者应考虑早期节律控制以降低心血管结局。
  • 合并症较少的患者接受早期节律控制可能结局欠佳。

研究设计与样本

  • EAST-AFNET4随机对照试验的预设亚组分析。
  • 按CHA2DS2-VASc评分≥4(1093例,74.8±6.8岁,61%女性)与<4(1696例,67.4±8.0岁,37%女性)分层比较早期节律控制与常规治疗。
  • 敏感性分析采用忽略性别的CHA2DS2-VA评分。

主要发现

  • CHA2DS2-VASc≥4患者主要疗效终点事件:早期节律控制组127/549例,常规治疗组183/544例,HR 0.64(0.51-0.81),P<0.001。
  • CHA2DS2-VASc<4患者主要疗效终点事件:早期节律控制组122/846例,常规治疗组133/850例,HR 0.93(0.73-1.19),P=0.56,交互作用P=0.037。
  • CHA2DS2-VASc≥4患者主要安全终点事件:早期节律控制组112/549例,常规治疗组132/544例,HR 0.84(0.65-1.08),P=0.175。
  • CHA2DS2-VASc<4患者主要安全终点事件:早期节律控制组119/846例,常规治疗组91/850例,HR 1.39(1.05-1.82),P=0.019,交互作用P=0.008。
  • 危及生命事件或死亡在两组间无差异(CHA2DS2-VASc≥4:早期节律控制组84/549例,常规治疗组96/544例;<4:早期节律控制组75/846例,常规治疗组73/850例)。

关键数值与推荐

  • 主要疗效终点为心血管死亡、卒中或心衰恶化/急性冠脉综合征住院的复合终点。
  • 主要安全终点为死亡、卒中或节律控制治疗的严重不良事件。
  • 采用CHA2DS2-VA评分时,主要疗效终点交互作用P=0.25,主要安全终点交互作用P=0.044。

临床怎么用

  • 对近期诊断房颤且CHA2DS2-VASc评分≥4的患者,可考虑早期节律控制以降低心血管复合终点。
  • 对CHA2DS2-VASc评分<4的患者,早期节律控制可能增加主要安全终点事件,需谨慎权衡。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The randomized EAST-AFNET4 (Early Treatment of Atrial Fibrillation for Stroke Prevention Trial-Atrial Fibrillation Network) demonstrated that early rhythm control (ERC) reduces adverse cardiovascular outcomes in patients with recently diagnosed atrial fibrillation and stroke risk factors. The effectiveness and safety of ERC in patients with multiple cardiovascular comorbidities is not known. METHODS: These prespecified subanalyses of EAST-AFNET4 compared the effectiveness and safety of ERC with usual care (UC) stratified into patients with higher (CHA2DS2-VASc score ≥4) and lower comorbidity burden. Sensitivity analyses ignored sex (CHA2DS2-VA score). RESULTS: EAST-AFNET4 randomized 1093 patients with CHA2DS2-VASc score ≥4 (74.8±6.8 years, 61% female) and 1696 with CHA2DS2-VASc score <4 (67.4±8.0 years, 37% female). ERC reduced the composite primary efficacy outcome of cardiovascular death, stroke, or hospitalization for worsening of heart failure or for acute coronary syndrome in patients with CHA2DS2-VASc score ≥4 (ERC, 127/549 patients with events; UC, 183/544 patients with events; hazard ratio [HR], 0.64 [0.51-0.81]; P < 0.001) but not in patients with CHA2DS2-VASc score <4 (ERC, 122/846 patients with events; UC, 133/850 patients with events; HR, 0.93 [0.73-1.19]; P=0.56, Pinteraction=0.037). The primary safety outcome (death, stroke, or serious adverse events of rhythm control therapy) was not different between study groups in patients with CHA2DS2-VASc score ≥4 (ERC, 112/549 patients with events; UC, 132/544 patients with events; HR, 0.84 [0.65, 1.08]; P=0.175), but occurred more often in patients with CHA2DS2-VASc scores <4 randomized to ERC (ERC, 119/846 patients with events; UC, 91/850 patients with events; HR, 1.39 [1.05-1.82]; P=0.019, Pinteraction=0.008). Life-threatening events or death were not different between groups (CHA2DS2-VASc score ≥4, ERC, 84/549 patients with event, UC, 96/544 patients with event; CHA2DS2-VASc scores <4, ERC, 75/846 patients with event, UC, 73/850 patients with event). When female sex was ignored for the creation of higher and lower risk groups (CHA2DS2-VA score), the Pinteraction was not significant for the primary efficacy outcome (P=0.25), but remained significant (P=0.044) for the primary safety outcome. CONCLUSIONS: Patients with recently diagnosed atrial fibrillation and CHA2DS2-VASc score ≥4 should be considered for ERC to reduce cardiovascular outcomes, whereas those with fewer comorbidities may have less favorable outcomes with ERC. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT01288352. URL: https://www.clinicaltrialsregister.eu; Unique identifier: 2010-021258-20. URL: https://www.isrctn.com/; Unique identifier: ISRCTN04708680.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Rillig, Borof, Breithardt, et al. Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden. Circulation. 2022. PMID: 35968706. doi:10.1161/CIRCULATIONAHA.122.060274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。